Celsius - CELH Stock Forecast, Price & News

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Celsius in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CELH shares.
View CELH analyst ratings or view top-rated stocks.

6 Wall Street research analysts have issued 1-year price objectives for Celsius' shares. Their CELH share price forecasts range from $70.00 to $140.00. On average, they expect the company's stock price to reach $109.88 in the next year. This suggests a possible upside of 21.8% from the stock's current price.
View analysts price targets for CELH or view top-rated stocks among Wall Street analysts.

Celsius' stock was trading at $104.04 at the start of the year. Since then, CELH stock has decreased by 13.3% and is now trading at $90.24.
View the best growth stocks for 2023 here.

Celsius saw a increase in short interest during the month of February. As of February 28th, there was short interest totaling 9,580,000 shares, an increase of 5.4% from the February 13th total of 9,090,000 shares. Based on an average daily volume of 967,300 shares, the days-to-cover ratio is presently 9.9 days. Approximately 21.7% of the shares of the stock are short sold.
View Celsius' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 9th 2023.
View our CELH earnings forecast.

Celsius Holdings, Inc. (NASDAQ:CELH) issued its quarterly earnings results on Wednesday, March, 1st. The company reported $0.04 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.05) by $0.09. The business had revenue of $177.96 million for the quarter, compared to the consensus estimate of $176.13 million. Celsius had a negative net margin of 28.65% and a negative trailing twelve-month return on equity of 17.67%.

ETFs with the largest weight of Celsius (NASDAQ:CELH) stock in their portfolio include Global X Health & Wellness ETF (BFIT), Future Fund Active ETF (FFND), Invesco Dynamic Food & Beverage ETF (PBJ), Invesco DWA Consumer Staples Momentum ETF (PSL), VegTech Plant-based Innovation & Climate ETF (EATV), Invesco S&P MidCap 400 Pure Growth ETF (RFG), Pacer Lunt MidCap Multi-Factor Alternator ETF (PAMC) and Strategas Macro Thematic Opportunities ETF (SAMT).

Based on aggregate information from My MarketBeat watchlists, some companies that other Celsius investors own include Advanced Micro Devices (AMD), Tesla (TSLA), NVIDIA (NVDA), Block (SQ), AbbVie (ABBV), Pfizer (PFE), Applied Materials (AMAT), Gilead Sciences (GILD), PayPal (PYPL) and Cisco Systems (CSCO).

Celsius trades on the NASDAQ under the ticker symbol "CELH."

Celsius' stock is owned by a variety of institutional and retail investors. Top institutional investors include American Century Companies Inc. (1.30%), Geode Capital Management LLC (1.20%), Eagle Asset Management Inc. (1.18%), 1832 Asset Management L.P. (1.13%), Macquarie Group Ltd. (1.11%) and Voya Investment Management LLC (0.90%). Insiders that own company stock include Carl Desantis, Hal Kravitz, Hoi Shuen Solina Holly Chau, John Fieldly, Nicholas Castaldo and William H Milmoe.
View institutional ownership trends.

Shares of CELH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CELH stock can currently be purchased for approximately $90.24.

Celsius (NASDAQ:CELH) has a market capitalization of $6.92 billion and generates $653.60 million in revenue each year. The company earns $-187,280,000.00 in net income (profit) each year or ($2.62) on an earnings per share basis.

The company employs 225 workers across the globe.

Celsius' mailing address is 2424 NORTH FEDERAL HIGHWAY SUITE 208, BOCA RATON FL, 33431. The official website for the company is www.celsiusholdingsinc.com. The company can be reached via phone at (561) 276-2239, via email at ir@ampliphibio.com, or via fax at 561-276-2268.